School of Life Sciences, Northwestern Polytechnical University, Xi'an, China.
Department of Surgical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
J Food Biochem. 2022 Oct;46(10):e14302. doi: 10.1111/jfbc.14302. Epub 2022 Jul 11.
Cancer is a global health issue that is rising swiftly with younger people and an increased number of patients. The role of human microbiota in the pathophysiology of tumors has been paid more and more attention. Microecologics including prebiotics, probiotics, and synbiotics are among the best validated/proven resources for the application of microbiological prophylaxis and therapy. There is strong evidence that microecologics have anti-cancer activity and their potential association with cancer is significant. In this review, we will focus on the role of prebiotics, probiotics, and synbiotics in tumor suppression in maintaining the colon barrier, metabolism, immune regulation, inhibition of host tumor cell proliferation, and epidemiological-based recommendations. Besides, other signs illuminate the role of microecological agents to adjunct the cancer treatment and counter the toxic side effects of cancer drugs. In addition, we will explore their role in chemotherapy, where these probiotics can be used as an adjunct to chemotherapy, counteracting the toxic side effects of chemotherapy drugs to minimize or optimize the therapeutic effect. In the treatment of cancer, we can see the role of prebiotics, probiotics, synbiotics, and their application in cancer patients, and the effectiveness effect can be considered as a clinical benefit. PRACTICAL APPLICATIONS: A large number of studies have shown that microecologics including prebiotics, probiotics, and synbiotics play an important role in regulating intestinal microecology and contribute to the prevention and treatment of cancer, indicating that prebiotics, probiotics, and synbiotics have the potential to be used as microecological modulators in the adjuvant therapy of cancer. However, it is not clear what is the anti-tumor mechanism of these microecologics and how they antagonize the side effects of cancer chemotherapy and protect normal cells. This paper reviews the role of prebiotics, probiotics, and synbiotics in tumor suppression in maintaining the colon barrier, metabolism, immune regulation, and prevention of rapid growth of host cells, as well as their potential role in cancer chemotherapy. This review helps to better understand the relationship between prebiotics, probiotics, and synbiotics with immune regulation, intestinal microecology, metabolic regulation, and cell proliferation and provides strong evidence for their potential application as microecologics in cancer adjuvant therapy.
癌症是一个全球性的健康问题,其发病率在年轻人和患者数量方面迅速上升。人类微生物群在肿瘤病理生理学中的作用越来越受到关注。包括益生元、益生菌和合生菌在内的微生态制剂是微生物预防和治疗中最经过验证/证实的资源之一。有强有力的证据表明,微生态制剂具有抗癌活性,它们与癌症的潜在关联具有重要意义。在本综述中,我们将重点讨论益生元、益生菌和合生菌在抑制肿瘤生长、维持结肠屏障、代谢、免疫调节、抑制宿主肿瘤细胞增殖以及基于流行病学的建议方面的作用。此外,其他迹象表明,微生态制剂在辅助癌症治疗和对抗癌症药物的毒副作用方面具有重要作用。此外,我们还将探讨它们在化疗中的作用,这些益生菌可以作为化疗的辅助手段,对抗化疗药物的毒副作用,以最小化或优化治疗效果。在癌症治疗中,我们可以看到益生元、益生菌、合生菌及其在癌症患者中的应用的作用,并且可以将疗效效果视为临床获益。
大量研究表明,包括益生元、益生菌和合生菌在内的微生态制剂在调节肠道微生态方面发挥着重要作用,有助于癌症的预防和治疗,这表明益生元、益生菌和合生菌具有作为癌症辅助治疗的微生态调节剂的潜力。然而,目前尚不清楚这些微生态制剂的抗肿瘤机制是什么,以及它们如何拮抗癌症化疗的副作用并保护正常细胞。本文综述了益生元、益生菌和合生菌在维持结肠屏障、代谢、免疫调节和预防宿主细胞快速生长方面在肿瘤抑制中的作用,以及它们在癌症化疗中的潜在作用。这篇综述有助于更好地理解益生元、益生菌和合生菌与免疫调节、肠道微生态、代谢调节和细胞增殖的关系,并为它们作为癌症辅助治疗的微生态制剂的潜在应用提供了有力证据。